Ye Liu

Ye Liu serves as the Executive Director at REGENXBIO Inc. since November 2017, focusing on adeno-associated virus (AAV) gene therapy for various inherited conditions, along with AAV transgene cassette design and capsid engineering. Prior to this role, Ye Liu held several positions at NOVAVAX INC from June 2007 to November 2017, including Director of Genetic Engineering, Senior Manager of Genetic Engineering, and Senior Scientist, leading initiatives in molecular cloning, vaccine development, and recombinant virus-like particle vaccines. Ye Liu's academic background includes a Ph.D. in Biochemistry and Molecular Biology from The Johns Hopkins University and a B.S. in Biological Sciences and Biotechnology from Tsinghua University. A postdoctoral fellowship at Johns Hopkins University School of Medicine provided foundational experience in proteomics and protein modifications.